Clinical trial
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated…
NCT00107718 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00107718 |
|---|---|
| Title | Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma |
| Official title | A Phase II Study of IL-18 in Melanoma Patients |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | SB-485232 |
| Enrollment | 64 |
| Start date | Nov 15, 2004 |
| Primary completion | May 19, 2006 |
| Completion | May 19, 2006 |
| First posted | Apr 8, 2005 |
| Last update posted | Jul 27, 2017 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: